Brittany Weber1, Lourdes M Perez-Chada2, Sanjay Divakaran1, Jenifer M Brown1, Viviany Taqueti1, Sharmila Dorbala1, Ron Blankstein1, Katherine Liao3, Joseph F Merola2, Marcelo Di Carli4. 1. Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, USA. 2. Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, 75 Francis St, ASB-L1 037C, Boston, MA, 02115, USA. 3. Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Boston, USA. 4. Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, USA. mdicarli@bwh.harvard.edu.
Abstract
BACKGROUND: Psoriasis is a common chronic inflammatory skin disorder that is associated with excess cardiovascular risk. Inflammation is a key mediator in the onset and progression of these cardiometabolic abnormalities; however, the excess cardiovascular risk conferred by psoriatic disease remains understudied. We investigated the prevalence and severity of CMD in patients with psoriasis and determined whether CMD is a result of CV risk factors and atherosclerotic burden. METHODS: This was a consecutive retrospective cohort study of patients with psoriasis, normal myocardial perfusion, and LV ejection fraction (EF) > 50% (N = 62) and matched controls without psoriasis (N = 112). Myocardial perfusion and myocardial flow reserve (MFR) were quantified using PET imaging. Atherosclerotic burden was determined by semi-quantitative computed tomography (CT) coronary calcium assessment. RESULTS: The prevalence of CMD (defined as MFR < 2) was 61.3% in patients with psoriatic disease, compared to 38.4% in a matched control population (P = .004). Furthermore, patients with psoriasis had a more severe reduction in adjusted MFR (2.3 ± .81 vs 1.92 ± .65, respectively, P = .001). The degree of atherosclerotic burden, as assessed by qualitative calcium score, was similar between psoriasis and controls. CONCLUSIONS: Patients with psoriasis without overt CAD demonstrated a high prevalence of coronary vasomotor abnormalities that are not entirely accounted for by the commonly associated coronary risk factors or the burden of atherosclerosis.
BACKGROUND: Psoriasis is a common chronic inflammatory skin disorder that is associated with excess cardiovascular risk. Inflammation is a key mediator in the onset and progression of these cardiometabolic abnormalities; however, the excess cardiovascular risk conferred by psoriatic disease remains understudied. We investigated the prevalence and severity of CMD in patients with psoriasis and determined whether CMD is a result of CV risk factors and atherosclerotic burden. METHODS: This was a consecutive retrospective cohort study of patients with psoriasis, normal myocardial perfusion, and LV ejection fraction (EF) > 50% (N = 62) and matched controls without psoriasis (N = 112). Myocardial perfusion and myocardial flow reserve (MFR) were quantified using PET imaging. Atherosclerotic burden was determined by semi-quantitative computed tomography (CT) coronary calcium assessment. RESULTS: The prevalence of CMD (defined as MFR < 2) was 61.3% in patients with psoriatic disease, compared to 38.4% in a matched control population (P = .004). Furthermore, patients with psoriasis had a more severe reduction in adjusted MFR (2.3 ± .81 vs 1.92 ± .65, respectively, P = .001). The degree of atherosclerotic burden, as assessed by qualitative calcium score, was similar between psoriasis and controls. CONCLUSIONS: Patients with psoriasis without overt CAD demonstrated a high prevalence of coronary vasomotor abnormalities that are not entirely accounted for by the commonly associated coronary risk factors or the burden of atherosclerosis.
Authors: Caroline Chiles; Fenghai Duan; Gregory W Gladish; James G Ravenel; Scott G Baginski; Bradley S Snyder; Sarah DeMello; Stephanie S Desjardins; Reginald F Munden Journal: Radiology Date: 2015-03-09 Impact factor: 11.105
Authors: Stefano Piaserico; Elena Osto; Giulia Famoso; Roberta Montisci; Laura De Michieli; Irene Zanetti; Sabino Iliceto; Francesco Tona Journal: Atherosclerosis Date: 2019-08-23 Impact factor: 5.162
Authors: Farzad Alinaghi; Monika Calov; Lars Erik Kristensen; Dafna D Gladman; Laura C Coates; Denis Jullien; Alice B Gottlieb; Paolo Gisondi; Jashin J Wu; Jacob P Thyssen; Alexander Egeberg Journal: J Am Acad Dermatol Date: 2018-06-19 Impact factor: 11.527
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: Andrew J Einstein; Lynne L Johnson; Sabahat Bokhari; Jessica Son; Randall C Thompson; Timothy M Bateman; Sean W Hayes; Daniel S Berman Journal: J Am Coll Cardiol Date: 2010-11-30 Impact factor: 24.094
Authors: Ankur Gupta; Viviany R Taqueti; Tim P van de Hoef; Navkaranbir S Bajaj; Paco E Bravo; Venkatesh L Murthy; Michael T Osborne; Sara B Seidelmann; Tomas Vita; Courtney F Bibbo; Meagan Harrington; Jon Hainer; Ornella Rimoldi; Sharmila Dorbala; Deepak L Bhatt; Ron Blankstein; Paolo G Camici; Marcelo F Di Carli Journal: Circulation Date: 2017-09-01 Impact factor: 29.690
Authors: Joel M Gelfand; Andrea B Troxel; James D Lewis; Shanu Kohli Kurd; Daniel B Shin; Xingmei Wang; David J Margolis; Brian L Strom Journal: Arch Dermatol Date: 2007-12
Authors: Aditya A Joshi; Joseph B Lerman; Amit K Dey; Aparna P Sajja; Agastya D Belur; Youssef A Elnabawi; Justin A Rodante; Tsion M Aberra; Jonathan Chung; Taufiq Salahuddin; Balaji Natarajan; Jenny Dave; Aditya Goyal; Jacob W Groenendyk; Joshua P Rivers; Yvonne Baumer; Heather L Teague; Martin P Playford; David A Bluemke; Mark A Ahlman; Marcus Y Chen; Joel M Gelfand; Nehal N Mehta Journal: JAMA Cardiol Date: 2018-10-01 Impact factor: 14.676
Authors: Brittany N Weber; Emma Stevens; Lourdes M Perez-Chada; Jenifer M Brown; Sanjay Divakaran; Camden Bay; Courtney Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Viviany R Taqueti; Joseph F Merola; Elena Massarotti; Karen Costenbader; Katherine Liao; Marcelo F Di Carli Journal: JACC Cardiovasc Imaging Date: 2021-03-17
Authors: Francesco Tona; Elena Osto; Peter L M Kerkhof; Roberta Montisci; Giulia Famoso; Giulia Lorenzoni; Laura De Michieli; Annagrazia Cecere; Irene Zanetti; Giovanni Civieri; Sabino Iliceto; Stefano Piaserico Journal: Eur J Clin Invest Date: 2021-11-25 Impact factor: 5.722